Webinar: Debate on the future of treatment for drug-resistant TB
So far, different standardised regimens are prescribed according to the status of the patient (new or previously treated) and/or the resistance of the bacilli: the cascade approach. These days, the TB drug pipeline is the best it has been for at least the last decade and there are currently numerous clinical trials underway looking at new drugs and new combinations for the treatment of TB. Does this re-invigorated drug pipeline allow for a change in approach to the management of drug-resistant TB moving away from the cascade approach to using the strongest possible regimens in the initial treatment of drug-resistant TB?
Please join Dr Arnaud Trebucq and Dr Grania Brigden to debate the future for drug-resistant TB regimen approaches.
Date and time: Tuesday, 27 November 2018, 16:00-17:00 (Paris time)
Registration URL: https://attendee.gotowebinar.com/register/4069352302943920898
Webinar ID: 345-192-963
Facilitator: Paul Jensen (Director of Policy and Strategy, The Union)
Objectives:
1. Review the arguments in favour of the cascade approach
2. Review the arguments for a more “pan-TB” for all forms of DR-TB
3. Discuss the future of DR-TB treatment regimens.
Target audience:
Union Members; researchers, NTPs, clinicians, advocates, civil society
After registering, you will receive a confirmation email containing information about joining the webinar.
